EMPOWER-lung 1: A randomized, open-label, multi-national, phase
III trial of cemiplimab, a human PD-1 monoclonal antibody, versus
chemotherapy in first-line treatment of advanced non-small cell lung
cancer (NSCLC) with PD-L1 50%
- Publication date
- 1 December 2018
- Publisher